As an attending hematopathologist I am involved in diagnostic work up and follow up after therapy of patients diagnosed with hematologic malignancies including AML, ALL, MDS and MDS/MPN. I am interested in understanding the pathogenesis of hematopoietic tumors and how specific events required for leukemic transformation can be targeted for therapy. In addition, as part of collaborative research projects I have been involved in the analyses of mice in models of normal and malignant hematopoiesis.
Department of Pathology, Univeristy of Chicago
Chicago
Fellowship - Hematopathology
2008
Department of Pathology, Univeristy of Chicago
Chicago
Residency - Clinical Pathology
2007
Ben May Department of Cancer Research, University of Chicago
Chicago
Post Doctoral Fellowship - Cancer Biology, Normal and Malignant Hematopoiesis
2004
INSERM U517, University of Burgundy
Dijon, France
Post Doctoral Fellowship - Cancer Biology, Apoptosis
2002
All India Institute of Medical Sciences
New Delhi, India
PhD - Hematology
2000
Motilal Nehru Medical College
Allahabad, India
MBBS - Medicine
1992
Microbiota may affect the tumor type but not overall tumor development in two models of heritable cancer.
Microbiota may affect the tumor type but not overall tumor development in two models of heritable cancer. bioRxiv. 2023 Oct 12.
PMID: 37873087
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
PMID: 36655425
Gata1s mutant mice display persistent defects in the erythroid lineage.
Gata1s mutant mice display persistent defects in the erythroid lineage. Blood Adv. 2023 07 11; 7(13):3253-3264.
PMID: 36350717
The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition.
The Times, They Are A-Changing: The Impact of Next-Generation Sequencing on Diagnosis, Classification, and Prognostication of Myeloid Malignancies With Focus on Myelodysplastic Syndrome, AML, and Germline Predisposition. Am Soc Clin Oncol Educ Book. 2023 Jun; 43:e390026.
PMID: 37307513
EBV-positive inflammatory FDC/FRC tumor: no longer pseudo or sarcoma!
EBV-positive inflammatory FDC/FRC tumor: no longer pseudo or sarcoma! Blood. 2023 02 23; 141(8):961.
PMID: 36821180
Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells.
Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells. Oncogene. 2023 03; 42(12):881-893.
PMID: 36725889
IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms.
IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood. 2022 12 29; 140(26):2805-2817.
PMID: 36283106
Lymphatic coagulation and neutrophil extracellular traps in lung-draining lymph nodes of COVID-19 decedents.
Lymphatic coagulation and neutrophil extracellular traps in lung-draining lymph nodes of COVID-19 decedents. Blood Adv. 2022 12 27; 6(24):6249-6262.
PMID: 35977099
Gata1s mutant mice display persistent defects in the erythroid lineage.
Gata1s mutant mice display persistent defects in the erythroid lineage. Blood Adv. 2022 Nov 09.
PMID: 36350717
Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.
PMID: 36240471